A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of Amyloid Depleter ALXN2220 in Adult Participants With Transthyretin Amyloid Cardiomyopathy (ATTR-CM)

Status: Recruiting

Phase of Trial: Phase III

Latest Information Update: 02 Mar 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs ALXN 2220 (Primary)
Indications Cardiomyopathies
Focus Registrational; Therapeutic Use
Acronyms DepleTTR-CM
Sponsors Alexion AstraZeneca Rare Disease

Most Recent Events

27 Sep 2024 Planned End Date changed from 30 Nov 2028 to 31 Oct 2028.
25 Jul 2024 Planned End Date changed from 31 Oct 2028 to 30 Nov 2028.
23 May 2024 Planned End Date changed from 25 Oct 2028 to 31 Oct 2028.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight